BEGIN:VCALENDAR
VERSION:2.0
PRODID:icalendar-ruby
CALSCALE:GREGORIAN
X-WR-CALNAME:[Rescheduled] Broad Discovery Series: The story behind a new t
 herapy for lung cancer patients
X-WR-TIMEZONE:Eastern Time (US & Canada)
BEGIN:VEVENT
DTSTAMP:20260521T112215Z
UID:tag:localist.com\,2008:EventInstance_52250522955123
DTSTART:20260318T220000Z
DTEND:20260319T000000Z
DESCRIPTION:Wednesday\, March 18th\n6:00 - 7:00 pm | Reception to Follow\n\
 nBroad Institute Auditorium + Discovery Center\n415 Main Street\, Cambridg
 e\, MA\n\nIn the early 2000s\, Broad Institute researchers found that the 
 EGFR protein is mutated in lung cancer\, sparking a revolution in targeted
  cancer treatment. But not all lung tumors respond to such treatments\, le
 aving many patients with few options. In this Broad Discovery Series event
 \, Heidi Greulich and Matthew Meyerson will describe the 20-year history o
 f sevabertinib\, a new lung cancer drug (and the first FDA-approved drug b
 orn of Broad science) that blocks both EGFR and the related HER2 protein\;
  talk about the unmet need it fulfills\, discuss the unique partnership be
 hind its development\, and explore drug development's evolving challenges.
 \n\n\nTo attend virtually\, follow the link here at the time of the event.
GEO:42.362792;-71.08756
LOCATION:Merkin Building (415M)\, Auditorium + Broad Discovery Center (Lobb
 y)
SUMMARY:[Rescheduled] Broad Discovery Series: The story behind a new therap
 y for lung cancer patients
URL;VALUE=URI:http://events.broadinstitute.org/event/rescheduled-broad-disc
 overy-series-the-story-behind-a-new-therapy-for-lung-cancer-patients-5278
CATEGORIES:Talks
END:VEVENT
END:VCALENDAR